Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma
暂无分享,去创建一个
G. Reifenberger | F. Floeth | G. Stoffels | N. Galldiks | H. Steiger | K. Langen | A. Heinzel | M. Sabel | H. Coenen | J. Felsberg | M. Rapp | C. Ewelt | T. Beez | Christian Ewelt
[1] G. Fink,et al. Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI , 2012, The Journal of Nuclear Medicine.
[2] J. Tonn,et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[3] K. Langen,et al. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[4] John O. Prior,et al. Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and Metaanalysis , 2012, The Journal of Nuclear Medicine.
[5] Wolfgang A Weber,et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. , 2011, International journal of radiation oncology, biology, physics.
[6] R. Baum,et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading: Assessment of Individual Probability of Malignancy , 2011, Clinical nuclear medicine.
[7] Michael Sabel,et al. Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[8] C. Hartmann,et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. , 2011, Neuro-oncology.
[9] W. Brenner,et al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas , 2010, European Radiology.
[10] S. Weis,et al. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Lutz Tellmann,et al. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. , 2009, Nuclear medicine and biology.
[12] Soonmee Cha,et al. Neuroimaging in neuro-oncology , 2009, Neurotherapeutics.
[13] Christian Woiciechowsky,et al. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas , 2008, Journal of Neuro-Oncology.
[14] Jochen Herms,et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[15] G. Reifenberger,et al. Prognostic Value of O-(2-18F-Fluoroethyl)-l-Tyrosine PET and MRI in Low-Grade Glioma , 2007, Journal of Nuclear Medicine.
[16] G. Reifenberger,et al. 18F-FET PET differentiation of ring-enhancing brain lesions. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] Karl-Josef Langen,et al. O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. , 2006, Nuclear medicine and biology.
[18] W. Koch,et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] Karl-Josef Langen,et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.
[20] Hans-Jakob Steiger,et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. , 2005, Journal of neurosurgery.
[21] K. Hamacher,et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[22] Jörg-Christian Tonn,et al. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[23] Lutz Tellmann,et al. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] K. Hamacher,et al. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[25] A. Thiel,et al. 11C-methionine PET for differential diagnosis of low-grade gliomas , 1998, Neurology.
[26] J. Mukherjee,et al. 11C-l-Methionine Positron Emission Tomography in the Clinical Management of Cerebral Gliomas , 2007, Molecular Imaging and Biology.
[27] M Schwaiger,et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.